The European & Developing Countries Clinical Trials Partnership (EDCTP) is a public-public partnership between countries in Europe and sub-Saharan Africa, and the European Union.
The programme aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials.
EDCTP was established in 2003 as a research programme undertaken by 16 European countries with the support of the European Union in response to the global health crisis caused by HIV, tuberculosis and malaria. It was the largest programme targeting clinical trials in sub-Saharan Africa under the EU’s 6th Framework Programme for Research. The first EDCTP programme closed in December 2015.
EDCTP’s second programme runs from 2014 to 2024 and supports health services optimisation research as well as product-focused implementation research, for new or improved medical interventions against poverty-related and neglected infectious diseases, including advanced testing and field validation of new diagnostic tools.
Research and regulatory capacity development are a strong element of the EDCTP’S research funding strategy in order to strengthen the conditions for conducting clinical research in sub-Saharan Africa.
The EDCTP programme is executed through partnerships between European and African institutions and researchers in collaboration with the pharmaceutical industry and like-minded organisations. It is implemented as part of the European Framework Programme for Research and Innovation, Horizon 2020, and governed by the participating African and European countries.
The topics for most EDCTP calls for proposals are broad and non-disease specific to maintain flexibility in financing. This allows for timely funding of clinical trials of promising candidate drugs or vaccines, accommodating unexpected approaches and novel ideas, as well as supporting a response to emerging infectious diseases.
EDCTP calls for proposals are open to participation of researchers globally provided they team up with European and sub-Saharan African partners. Only researchers and/or institutions from sub-Saharan Africa, the European Union or one of the countries associated to Horizon 2020 are eligible to receive and administer EDCTP funding directly. The funding of projects is based on annual work plans and the priorities outlined in the EDCTP2 Strategic Business Plan.
Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation works with partner organizations worldwide to tackle critical problems in four program areas. Our Global Development Division works to help the world’s poorest people lift themselves out of hunger and poverty. Our Global Health Division aims to harness advances in science and technology to save lives in developing countries. Our United States Division works to improve U.S. high school and postsecondary education and support vulnerable children and families in Washington State. And our Global Policy & Advocacy Division seeks to build strategic relationships and promote policies that will help advance our work. Our approach to grantmaking in all four areas emphasizes collaboration, innovation, risk-taking, and, most importantly, results.
The Foundation for the National Institutes of Health
The Foundation for the National Institutes of Health creates and manages alliances with public and private institutions in support of the mission of the NIH, the world’s premier medical research agency. The Foundation, also known as the FNIH, works with its partners to accelerate biomedical research and strategies against diseases and health concerns in the United States and across the globe. The FNIH organizes and administers research projects; supports education and training of new researchers; organizes educational events and symposia; and administers a series of funds supporting a wide range of health issues. Established by Congress in 1990, the FNIH is a not-for-profit 501(c)(3) charitable organization. For additional information about the FNIH, please visit fnih.org.
National Institute of Allergy and Infectious Diseases
The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. For more than 60 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and around the world. NIAID is one of the 27 Institutes and Centers of the National Institutes of Health (NIH).
Grand Challenges China
Grand Challenges China was launched in partnership by the Bill & Melinda Gates Foundation and the National Natural Science Foundation of China (NSFC). The program focuses on innovative concepts for safe, effective, affordable and widely utilized interventions, such as vaccines and therapeutics, with the potential to protect against the acquisition, progression or transmission of infectious diseases that disproportionately affect the world’s poorest. It funds grants to collaborations comprised of teams at Chinese-based institutions and those based outside of China.
NIH’s International Collaborations in Infectious Disease Research (ICIDR) Program
The International Collaborations in Infectious Disease Research (ICIDR) Program, initiated in 1980, makes awards to U.S. institutions to engage in substantial international collaboration with overseas institutions in tropical medicine and emerging infectious disease research. The goals of the ICIDR program are to: support high-quality, collaborative research that will lead to or result in prevention, amelioration, and/or improved treatment of infectious diseases; increase relevant and collaborative research experience for both U.S. and foreign investigators; and facilitate and enhance scientific linkages between U.S. and foreign investigators to enhance the independent research capacity of the collaborating foreign institutions and foster further international collaborative research projects.
Consortium for TB Biomarkers
The Consortium for TB Biomarkers (CTB2) comprises the Global Alliance for TB Drug Development, the TB Trials Consortium, and the AIDS Clinical Trials Group. The CTB2 has created a collaborative biobank in order to accelerate the development of new drugs and treatments for tuberculosis by validating and exploring biomarkers of response to TB drug treatments. The biobank will ultimately house biospecimens from 1000 adult patients in long-term storage for use by the TB research community. Details about the biospecimens available for use in your research can be found here.